ATTD 2022: Mic Drop Moment As Medtronic Presents 780G Data Proving Closed Loop Ability
Results of the ADAPT study presented at the Advanced Technologies & Treatments for Diabetes conference in Barcelona support Medtronic’s hope that the 780g insulin pump will help to turn around its diabetes business or make it an attractive acquisition for another company.
You may also be interested in...
Ohad Cohen, director of medical affairs for Medtronic Diabetes EMEA, talked to Medtech Insight about the published results from the ADAPT trial, which showed that Medtronic’s advanced hybrid closed loop insulin delivery technology provides better glycemic control than standard therapies.
Postmarket data from Europe and Chile, announced at the American Diabetes Association conference, offer more support for Medtronic’s faith in its MiniMed 780G system with the Guardian 4 sensor.
The new independent kidney-care company will be equally co-owned by both companies. It will include all of Medtronic’s renal care solutions business, including renal access, acute therapies, and chronic therapies.